Pharma Mar SA (PHM) - Financial and Strategic SWOT Analysis Review

  • ID: 4239743
  • SWOT Analysis
  • 50 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • CTI BioPharma Corp
  • GP Pharm SA
  • Oryzon Genomics SA
  • MORE
Pharma Mar SA (PHM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar’s developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; PM1183 (lurbinectedin) for ovarian cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.

Pharma Mar SA Key Recent Developments

Apr 26, 2018: Pharmamar Group Reports First Quarter Financial Results
Feb 28, 2018: PharmaMar group announces 2017 earnings results
Oct 24, 2017: Pharma Mar group revenues totalled €140 million in the first nine months of the year
Jul 26, 2017: Pharma Mar group reports first half financial results
Jun 29, 2017: PharmaMar Group reviews 2016 at its annual general shareholders meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • CTI BioPharma Corp
  • GP Pharm SA
  • Oryzon Genomics SA
  • MORE
Section 1 - About the Company
  • Pharma Mar SA - Key Facts
  • Pharma Mar SA - Key Employees
  • Pharma Mar SA - Key Employee Biographies
  • Pharma Mar SA - Major Products and Services
  • Pharma Mar SA - History
  • Pharma Mar SA - Company Statement
  • Pharma Mar SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Pharma Mar SA - Business Description
  • Business Segment: Biopharmaceuticals
  • Overview
  • Performance
  • Business Segment: Consumer Chemicals
  • Overview
  • Performance
  • Geographical Segment: Germany
  • Performance
  • Geographical Segment: Italy
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Rest of the European Union
  • Performance
  • Geographical Segment: Rest of the World
  • Performance
  • Geographical Segment: Spain
  • Performance
  • Geographical Segment: the US
  • Performance
  • R&D Overview
  • Pharma Mar SA - Corporate Strategy
  • Pharma Mar SA - SWOT Analysis
  • SWOT Analysis - Overview
  • Pharma Mar SA - Strengths
  • Pharma Mar SA - Weaknesses
  • Pharma Mar SA - Opportunities
  • Pharma Mar SA - Threats
  • Pharma Mar SA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Pharma Mar SA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 26, 2018: Pharmamar Group Reports First Quarter Financial Results
  • Feb 28, 2018: PharmaMar group announces 2017 earnings results
  • Oct 24, 2017: Pharma Mar group revenues totalled €140 million in the first nine months of the year
  • Jul 26, 2017: Pharma Mar group reports first half financial results
  • Jun 29, 2017: PharmaMar Group reviews 2016 at its annual general shareholders meeting
  • Apr 27, 2017: PharmaMar Demonstrates Its Progress in R&D in New York
  • Apr 27, 2017: PharmaMar Group reports €45.5 million in revenues (+8%)
  • Mar 29, 2017: The success of sarcoma treatment, seen by prestigious international oncologists
  • Feb 24, 2017: PharmaMar continues to execute commercially in 2016, adds new partner for pipeline asset, and sees pipeline progress
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Pharma Mar SA, Key Facts
  • Pharma Mar SA, Key Employees
  • Pharma Mar SA, Key Employee Biographies
  • Pharma Mar SA, Major Products and Services
  • Pharma Mar SA, History
  • Pharma Mar SA, Subsidiaries
  • Pharma Mar SA, Key Competitors
  • Pharma Mar SA, Ratios based on current share price
  • Pharma Mar SA, Annual Ratios
  • Pharma Mar SA, Annual Ratios
  • Pharma Mar SA, Annual Ratios
  • Pharma Mar SA, Interim Ratios
  • Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Pharma Mar SA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Pharma Mar SA, Performance Chart (2013 - 2017)
  • Pharma Mar SA, Ratio Charts
  • Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Traslational Cancer Drugs Pharma SL
  • Oryzon Genomics SA
  • GP Pharm SA
  • CTI BioPharma Corp
  • Ariad Pharmaceuticals (Spain) SL
  • Ability Pharmaceuticals SL
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll